Neurocrine Biosciences NBIX Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's business segments — net income?
- Neurocrine Biosciences (NBIX) reported business segments — net income of $197.9M in Q1 2026.
- How has Neurocrine Biosciences's business segments — net income changed year-over-year?
- Neurocrine Biosciences's business segments — net income increased by 2405.1% year-over-year, from $7.9M to $197.9M.
- What is the long-term trend for Neurocrine Biosciences's business segments — net income?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — net income has grown at a 45.8% compound annual growth rate (CAGR), from $154.5M to $478.6M.
- What does business segments — net income mean?
- The bottom-line profit remaining after all operating expenses, taxes, and non-operating costs are deducted from total revenue. This is the primary indicator of the company's overall financial health and profitability.